Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERROGATE-GBM: PEP-CMV Vaccine in Glioblastoma
NCT06132438Phase 1Recruiting
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEP-CMV in glioblastoma (GBM). Primary endpoint: Percentage of participants with treatment-related adverse events at 12 weeks. Started Jul 2024; status: recruiting.
02
Drugs
PEP-CMV
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06132438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132438.